JNJ keeping prices for #Subcutaneous #Daratumumab in line with the IV version. Building market share means a margin cut for $JNJ as they now also have to pay $HALO for the SC. 

#Genmab: Janssen fastholder prisen på ny version af Darzalex  $GMAB https://t.co/4fiJnnbYnm